# Cardiovascular Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/cardiovascular-disease

> 10 upcoming FDA catalysts in cardiovascular Disease: AZD0780 (AZN) on Jan to Apr 2027 (topline data readout); AZD0780 (AZN) on January 2027 (primary completion); Wegovy (semaglutide, NVO) on September 2027 (primary completion); Wegovy (semaglutide, NVO) on Sep to Dec 2027 (topline data readout); and 6 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Jan to Apr 2027 | [AZD0780 topline data readout](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000123 (A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000123)) |
| January 2027 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000123 (A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-11 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000123)) |
| September 2027 | [Wegovy (semaglutide) primary completion](https://sec-api.dev/pdufa/semaglutide) | NVO | Cardiovascular Disease | scheduled | "NCT05669755 (REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669755)) |
| Sep to Dec 2027 | [Wegovy (semaglutide) topline data readout](https://sec-api.dev/pdufa/semaglutide) | NVO | Cardiovascular Disease | scheduled | "NCT05669755 (REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-01 (ESTIMATED); Lead Sponsor Novo Nordisk A/S." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05669755)) |
| Jun to Sep 2028 | [Olpasiran topline data readout](https://sec-api.dev/pdufa/olpasiran) | AMGN | Cardiovascular Disease | scheduled | "NCT07293260 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07293260)) |
| June 2028 | [Olpasiran primary completion](https://sec-api.dev/pdufa/olpasiran) | AMGN | Cardiovascular Disease | scheduled | "NCT07293260 (Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction - Coronary Computed Tomography Angiography Trial): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Amgen." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07293260)) |
| May to Aug 2029 | [Adjuvanted rzv vaccine topline data readout](https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine) | GSK | Cardiovascular Disease | scheduled | "NCT07712380 (A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07712380)) |
| May 2029 | [Adjuvanted rzv vaccine primary completion](https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine) | GSK | Cardiovascular Disease | scheduled | "NCT07712380 (A Study Exploring the Effect of Adjuvanted RZV or RSVPreF3 Vaccines on Coronary Plaque Progression in Adults >=50 Years of Age at Risk for Cardiovascular Events): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-05-02 (ESTIMATED); Lead Sponsor GlaxoSmithKline." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07712380)) |
| Oct 2029 to Jan 2030 | [AZD0780 topline data readout](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000357 (A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000357)) |
| October 2029 | [AZD0780 primary completion](https://sec-api.dev/pdufa/azd0780) | AZN | Cardiovascular Disease | scheduled | "NCT07000357 (A Phase III Study of AZD0780 on Major Adverse CV Events in Patients With a History of ASCVD Events or at High Risk for a First Event): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07000357)) |

## Drugs

- [AZD0780](https://sec-api.dev/pdufa/azd0780) (AZN)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [Olpasiran](https://sec-api.dev/pdufa/olpasiran) (AMGN)
- [Adjuvanted rzv vaccine](https://sec-api.dev/pdufa/adjuvanted-rzv-vaccine) (GSK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/cardiovascular-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cardiovascular Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/cardiovascular-disease

```bibtex
@misc{secapidev_indications_cardiovascular_disease_20261116,
  title        = {Cardiovascular Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/cardiovascular-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_cardiovascular_disease_20261116","title":"Cardiovascular Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/cardiovascular-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
